Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
@schettinif87.bsky.social
Medical oncologist 🩺 and postdoc researcher🧬at @hospitalclinic.bsky.social / @idibaps.bsky.social & collab @ub.edu, #EACR ambassador #ESMOFellow2020 #SOLTIYoung board member. Focus #intrinsicsubtypes #biomarkerdevelopment #HER2low #breastcancer #microbiome
Pinned
“Do, or do not. There is no try”
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Redirecting
doi.org
January 6, 2025 at 4:32 PM
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Excellent work published in#ESMOOpen by #ChernyNI et al.👇🏻
doi.org/10.1016/j.es...
Now that it’s official, I can finally celebrate: I’ve been awarded a Juan Rodés contract starting in 2025, ranking 1st in 🇪🇸!
Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸!
Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸!
December 30, 2024 at 8:23 AM
Now that it’s official, I can finally celebrate: I’ve been awarded a Juan Rodés contract starting in 2025, ranking 1st in 🇪🇸!
Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸!
Ahora que es oficial, por fin puedo celebrarlo: me han concedido un contrato Juan Rodés a partir de 2025, ocupando el primer puesto en 🇪🇸!
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
December 11, 2024 at 9:42 PM
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
December 11, 2024 at 12:26 AM
At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
My first takeaway from #SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2 👇🏻
December 11, 2024 at 11:38 PM
My first takeaway from #SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2 👇🏻
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
⭐️Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis www.thelancet.com/journals/lan...
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis
Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score,
defined as indicating substantial clinical benefit, increased the likelihood of a
positive HTA outcome and short...
www.thelancet.com
December 3, 2024 at 1:00 PM
⭐️Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis www.thelancet.com/journals/lan...
Big changes are coming…
Adjuvant ribociclib has been approved by EMA for HR+/HER2- early breast cancer, based on the results of NATALEE
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
November 29, 2024 at 8:59 AM
Big changes are coming…
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
One of the most important multi-cancer analyses on #ImmuneRelatedAdverseEvent grading and clinical outcome is out this week from @JNCI : https://buff.ly/499OIBj
November 26, 2024 at 3:54 AM
One of the most important multi-cancer analyses on #ImmuneRelatedAdverseEvent grading and clinical outcome is out this week from @JNCI : https://buff.ly/499OIBj
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
Review: The present and future of bispecific antibodies for cancer therapy
The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery
Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...
www.nature.com
November 27, 2024 at 3:46 AM
Review: The present and future of bispecific antibodies for cancer therapy
Finally out in @ESMO_Open the main findings of my #ESMO #Fellowship research project focused on the
identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer.
What did we find? A thread 🧵
identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer.
What did we find? A thread 🧵
November 28, 2024 at 7:11 AM
Finally out in @ESMO_Open the main findings of my #ESMO #Fellowship research project focused on the
identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer.
What did we find? A thread 🧵
identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer.
What did we find? A thread 🧵
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
Ready for the #envisionsummit2024 from #SOLTI with great speakers diving deep into the future of prognostic/predictive biomarkers in #breastcancer and new treatment strategies
November 22, 2024 at 12:57 PM
Ready for the #envisionsummit2024 from #SOLTI with great speakers diving deep into the future of prognostic/predictive biomarkers in #breastcancer and new treatment strategies
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
Aneuploid cells were primarily associated w/luminal epithelial lineages and localized in ductal & lobular structures without apparent histopathological abnormalities. Suggests clonal expansions of aneuploid cells are a normal feature of healthy breast tissues. #BreastCancer
https://buff.ly/3V1rbwT
https://buff.ly/3V1rbwT
November 21, 2024 at 2:07 PM
Aneuploid cells were primarily associated w/luminal epithelial lineages and localized in ductal & lobular structures without apparent histopathological abnormalities. Suggests clonal expansions of aneuploid cells are a normal feature of healthy breast tissues. #BreastCancer
https://buff.ly/3V1rbwT
https://buff.ly/3V1rbwT
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
ACOG recommends starting mammography at age 40 for those at average breast cancer risk, due to a 2% annual increase in cases among women aged 40-49 from 2015 to 2019. This update aligns with other major health organizations, advising continued screening every 1 to 2 years.
https://buff.ly/3UVMgJ0
https://buff.ly/3UVMgJ0
November 16, 2024 at 12:48 PM
ACOG recommends starting mammography at age 40 for those at average breast cancer risk, due to a 2% annual increase in cases among women aged 40-49 from 2015 to 2019. This update aligns with other major health organizations, advising continued screening every 1 to 2 years.
https://buff.ly/3UVMgJ0
https://buff.ly/3UVMgJ0
Effective summary of what we usually call a visceral crisis in #breastcancer
November 21, 2024 at 7:22 AM
Effective summary of what we usually call a visceral crisis in #breastcancer
Useful updated treatment algorithms for HR+ #breastcancer from @ilanaschlam.bsky.social
We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)
We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)
📌
November 20, 2024 at 6:48 AM
Useful updated treatment algorithms for HR+ #breastcancer from @ilanaschlam.bsky.social
We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)
We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)
Reposted by Francesco Schettini, MD, PhD 🇮🇹🇪🇸🇪🇺
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs
Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages.
https://buff.ly/3ZbZyU2
Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages.
https://buff.ly/3ZbZyU2
November 19, 2024 at 10:47 AM
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs
Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages.
https://buff.ly/3ZbZyU2
Findings suggest many prefer waiting for more evidence of survival benefits, challenging the accelerated approval pathway for cancer drugs lacking clear survival advantages.
https://buff.ly/3ZbZyU2
Great opportunity to learn and share your work! 👇🏻
Submit your abstract by 16 December for our upcoming virtual conference 'Drugging and Regulating the MAP Kinase Pathway' with Boehringer Ingelheim!
Don't miss the opportunity to showcase your research: eacr.org/conference/b...
#CancerResearch
Don't miss the opportunity to showcase your research: eacr.org/conference/b...
#CancerResearch
November 19, 2024 at 12:51 PM
Great opportunity to learn and share your work! 👇🏻
Ok let’s see how this app works. First post (taken from De Ashley Rubin, who I think is not on 🦋) very nice and helpful for researchers “lost in descriptionland”. I’ll use screenshots of her X thread.
November 19, 2024 at 8:57 AM
Ok let’s see how this app works. First post (taken from De Ashley Rubin, who I think is not on 🦋) very nice and helpful for researchers “lost in descriptionland”. I’ll use screenshots of her X thread.
“Do, or do not. There is no try”
November 17, 2024 at 9:12 AM
“Do, or do not. There is no try”